🏛️ Verified NIH Record • Updated 2026-03-16
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (NCT05610891)
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Cellectar Biosciences, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 10 Years to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Stanford University — Palo Alto, California
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- UT Southwestern Medical Center — Dallas, Texas
- Texas Children's Cancer Center, Baylor College of Medicine — Houston, Texas
- University of Wisconsin, Carbone Cancer Center — Madison, Wisconsin
- Hospital for Sick Children — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in High-Grade Glioma
- Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma — Santa Monica, California
- A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors — Basking Ridge, New Jersey
- Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac — New York, New York
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) — Gainesville, Florida
- Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas — New York, New York
Explore by condition: All High-Grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.